Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression Posted on January 10, 2022 By KEYTRUDA Showed Significant Improvement in Disease-Free Survival as Adjuvant Treatment for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression News
